The frequent co-expression of LAG-3 with other immune checkpoint inhibitors such as PD1, PD-L1, CTLA-4, and TIM-3 [47,52] strongly indicates that LAG-3 might contribute to immune escape mechanisms in cancer. The gene discussed is HAVCR2; the disease is cancer.